Zimbabwe has rejected a substantial US health deal worth 367 million US dollars (272 million pounds) over five years due to Washington's insistence on sensitive biological samples.
The decision became public following a internal memorandum from December was disclosed, indicating that President Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official spokesman later explained that the United States was seeking biological samples for research and profit but was unwilling to guarantee the resulting advantages from any future treatments.
"We are forced to start the challenging and unfortunate task of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had furnished over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has urged further dialogue to reach a deal agreeable to both sides so the nation's vital HIV treatment initiative can proceed.
Wider Context
This development follows a similar situation in neighbouring Kenya, where a high court halted a related deal with the US following concerns were filed about the security of citizens' medical information.
Since resuming office last year, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
USAID had administered aid for the US government, but Trump claimed its spending was "inefficient" and his government was pursuing government-to-government agreements to boost openness and responsibility.
As per statements, 16 nations in Africa have so far agreed to similar agreements, constituting over $18.3bn of fresh investment.
Details of the Rejected Agreement
The money for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership might have yielded immense advantages for the people of Zimbabwe, particularly the 1.2 million currently receiving HIV treatment via American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, without any corresponding assurance of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that shared data," Mangwana explained.
"Put simply, our country would supply the basic resources for medical research without any certainty that the final treatments would be available to our people should a new health crisis arise."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were undermining structures previously set up via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing framework designed to deal with potential global health emergencies.
"This framework is designed to ensure that when a country provides its data, the benefits – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as hostility towards the US," he added.
"We encourage ongoing discussions with our US partners on how future collaboration might be structured in a manner that respects the sovereignty and dignity of each country."
Medical Community Reaction
A leading public health body stated it recognised the official position, but suggested that negotiations need to persist considering a large portion of the country's HIV programmes relied on foreign aid.
"Where technical issues exist, including those involving data governance or implementation frameworks, these can frequently be addressed via technical clarification and mutually agreed protections," it commented.
The situation underscores the ongoing challenges between accepting vital foreign assistance and safeguarding local interests in an increasingly data-driven world.